Bremsstrahlung Imaging: A Valid Alternative For Dose Estimation In Patients Undergoing 90Y Zevalin Treatment

被引：0
|
作者：
Arrichiello, C. [1 ]
Mormile, M. [1 ]
D'Ambrosio, L. [1 ]
De Martinis, F. [1 ]
Squame, E. [1 ]
Frigeri, F. [1 ]
Arcamone, M. [1 ]
Aurilio, M. [1 ]
Aloj, L. [1 ]
Lastoria, S. [1 ]
机构：
[1] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S262 / S262
页数：1
相关论文
共 50 条
  • [41] TREATMENT WITH YTTRIUM-90 (90Y)-IBRITUMOMAB TIUXETAN (ZEVALIN®) IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 700 - 700
  • [42] Dosimetry and survival in unresectable primary HCC patients undergoing resin 90Y SIRT
    Santoro, Miriam
    Della Gala, Giuseppe
    Paolani, Giulia
    Rizzini, Elisa Lodi
    Golemi, Arber
    Cappelli, Alberta
    Mosconi, Cristina
    Calderoni, Letizia
    Tabacchi, Elena
    Rea, Sandra
    Ungania, Sara
    Sciuto, Rosa
    Strigari, Lidia
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2203 - S2205
  • [43] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).
    Schilder, RJ
    Witzig, TE
    Flinn, I
    Gordon, LI
    Emmanouilides, C
    Wang, H
    Vo, K
    Molina, A
    BLOOD, 2004, 104 (11) : 719A - 719A
  • [44] Angiographic considerations in patients undergoing liver-directed radioembolization with 90Y microspheres
    Maleux, G.
    Heye, S.
    Vaninbroukx, J.
    Deroose, C.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2010, 73 (04) : 489 - 496
  • [45] Monte Carlo simulation of 90Y PET imaging requires the modelling of internal bremsstrahlung and of long energy resolution tail
    Walrand, S.
    Hesse, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S461 - S461
  • [46] Monte Carlo simulation of radiation dose emission by patients administered with 90Y labelledradiopharmaceuticals
    Lo Meo, S.
    Cicoria, G.
    Bergamini, C.
    Pancaldi, D.
    Panebianco, A. S.
    Campanella, F.
    Marengo, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S210 - S210
  • [47] Optimization of energy window for 90Y bremsstrahlung SPECT imaging for detection tasks using the ideal observer with model-mismatch
    Rong, Xing
    Ghaly, Michael
    Frey, Eric C.
    MEDICAL PHYSICS, 2013, 40 (06)
  • [48] Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma.
    Sweetenham, JW
    Dicke, K
    Arcaroli, J
    Kogel, K
    Rana, TM
    Rice, LL
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [49] Phase I trial of combination therapy with 90Y ibritumomab tiuxetan (Zevalin) and gemicitabine in patients with non-hodgkin's lymphoma
    Borghaei, Hossein
    Smith, MitchellR.
    Millenson, Michael
    Thibodeau, Linda
    Kamiensky, Nicole
    Schilder, Russell J.
    BLOOD, 2007, 110 (11) : 192B - 193B
  • [50] Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging
    Erwin, William D.
    Esmaeli, Bita
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (09) : 681 - 686
12345